[18F]-AV-1451 Shows Staging Potential in Alzheimer's

This article originally appeared here.
Share this content:
[<sup>18</sup>F]-AV-1451 Shows Staging Potential in Alzheimer's
[18F]-AV-1451 Shows Staging Potential in Alzheimer's

MONDAY, Aug. 1, 2016 (HealthDay News) -- Use of [18F]-AV-1451 positron emission tomography (PET) can potentially stage Alzheimer's disease (AD), according to a study published online July 25 in JAMA Neurology.

In an effort to assess the usefulness of [18F]-AV-1451 PET imaging to stage AD, Liang Wang, M.D., from Washington University in St. Louis, and colleagues conducted an imaging study among 59 participants who were cognitively normal (CN) or had AD dementia.

The researchers found that the [18F]-AV-1451 standardized uptake value ratio (SUVR) in the hippocampus and AD cortical signature regions was able to differentiate AD from CN participants (area under the receiver operating characteristic curve range, 0.89 to 0.98). Cerebrospinal fluid Aβ42-positive (Aβ+) AD was best separated from cerebrospinal fluid Aβ42-negative CN participants at an [18F]-AV-1451 SUVR cut-off of 1.19 from AD cortical signature regions (sensitivity, 100 percent; specificity, 86 percent). This cut-off was also able to divide Aβ+ CN participants into high or low tau groups. In AD cortical signature regions, but not the hippocampus, the presence of Aβ+ correlated with elevated [18F]-AV-1451 SUVR. In both the hippocampus and AD cortical signature regions, an elevated [18F]-AV-1451 correlated with volumetric loss. In the hippocampus, but not AD cortical signature regions, the [18F]-AV-1451 volumetric association was modified by Aβ status.

"Aβ interacts with hippocampal and cortical tauopathy to affect neurodegeneration," the authors write. "In the absence of Aβ, hippocampal tau deposition may be insufficient for the neurodegenerative process that leads to AD."

Several authors disclosed financial ties to pharmaceutical companies, including Avid Radiopharmaceuticals, a wholly owned subsidiary of Eli Lilly, which provided AV-1451, radiochemistry support, and cross-referencing of the investigational new drug application.

Abstract
Full Text
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

SABCS: Artificial Intelligence May Aid Doctors in Breast Cancer Care

SABCS: Artificial Intelligence May Aid Doctors in Breast ...

'Watson Oncology' agreed with doctors 90 percent of the time in many cases, researchers find

SABCS: Scalp-Cooling System Can Reduce Chemo-Related Hair Loss

SABCS: Scalp-Cooling System Can Reduce Chemo-Related Hair Loss

Devices reduce blood flow to hair follicles during chemotherapy treatments

SABCS: Aromatase Inhibitors Tied to Reduced Endothelial Function

SABCS: Aromatase Inhibitors Tied to Reduced Endothelial Function

Women on aromatase inhibitors exhibit less elasticity in their blood vessels

is free, fast, and customized just for you!

Already a member?

Sign In Now »